Skip to main content

Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy

Japanese Journal of Radiology volume 34, pages 35–42 (2016)Cite this article

Abstract

Objectives

Whether chemoradiotherapy (CRT) is clinically beneficial for the management of postoperative recurrence of advanced gastric cancer remains unclear. We retrospectively studied treatment outcomes in patients who had unresectable localized recurrence after surgery for advanced gastric cancer and evaluated the safety and efficacy of CRT.

Methods

The study group comprised 21 patients who received concurrent CRT for unresectable localized recurrence after undergoing R0 resection for stage II/III advanced gastric cancer. Localized recurrence was defined as a few or limited recurrent lesions.

Results

The recurrence pattern was anastomotic recurrence in 7 patients, abdominal lymph-node recurrence in 12, and anastomotic recurrence plus abdominal lymph-node recurrence in 2. The median total dose of radiotherapy was 48.6 Gy (range 39.6–56.0), and the CRT completion rate was 100 % (21 of 21 patients). CRT-related grade 3 or higher toxicity comprised neutropenia in 33.3 % of patients and anorexia in 9.5 %. The response rate was 61.9 % (complete response 38.1 %, partial response 23.8 %). The median overall survival was 35.0 months.

Conclusions

We conclude that CRT may become one treatment strategy for the management of unresectable localized recurrence after curative resection of advanced gastric cancer.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2

References

  1. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127:2893–917.

    Article  CAS  PubMed  Google Scholar 

  2. Asaka M, Kato M, Graham DY. Prevention of gastric cancer by Helicobacter pylori eradication. Intern Med. 2010;49:633–6.

    Article  PubMed  Google Scholar 

  3. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med. 2001;345:725–30.

    Article  CAS  PubMed  Google Scholar 

  4. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG9904): quality of combined modality therapy and pathologic response. J Clin Oncol. 2006;24:3953–8.

    Article  CAS  PubMed  Google Scholar 

  5. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11–20.

    Article  CAS  PubMed  Google Scholar 

  6. Waddell T, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D. Gastric cancer: ESMO-ESSO-ESTRO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2013;24(Suppl 6):57–63.

    Article  Google Scholar 

  7. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Fujii M, Nashimoto A, et al. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med. 2007;357:1810–20.

    Article  CAS  PubMed  Google Scholar 

  8. Emami B, Lyman J, Brown A, Coia L, Goitein M, Munzenrider JE, et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiat Oncol Biol Phys. 1991;21:109–22.

    Article  CAS  PubMed  Google Scholar 

  9. Association Japanese Gastric Cancer. Japanese gastric cancer treatment guidelines 2010 (ver. 3). Gastric Cancer. 2011;14:113–23.

    Article  Google Scholar 

  10. Saikawa Y, Kubota T, Kumagai K, Nakamura R, Kumai K, Shigematsu N, et al. Phase II study of chemoradiotherapy with S-1 and low-dose cisplatin for inoperable advanced gastric cancer. Int J Radiat Oncol Biol Phys. 2008;71:173–9.

    Article  CAS  PubMed  Google Scholar 

  11. Akagi Y, Hashimoto Y, Murakami Y, Ito K. Concurrent chemoradiation experience of recurrent gastric cancers resistant to TS-1. Gan To Kagaku Ryoho. 2003;30:2107–13 (in Japanese).

    PubMed  Google Scholar 

  12. Yuan ST, Wang FL, Liu N, Liu YH, Liu SG, Huang Y, et al. Concurrent involved-field radiotherapy and XELOX versus XELOX chemotherapy alone in gastric cancer patients with postoperative locoregional recurrence. Am J Clin Oncol. 2015;38:130–4.

    Article  CAS  PubMed  Google Scholar 

  13. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228–47.

    Article  CAS  PubMed  Google Scholar 

  14. National Cancer Institute. Common terminology criteria for adverse events (CTCAE) ver 4.0. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE_4.03_2010-06-14_QuickReference_5x7.pdf. Accessed 26 Oct 2015.

  15. RTOG/EORTC late radiation morbidity scoring schema. http://www.rtog.org/ResearchAssociates/AdverseEventReporting/RTOGEORTCLateRadiationMorbidityScoringSchema.aspx. Accessed 26 Oct 2015.

  16. Koizumi W, Narahara H, Hara T, Takagane A, Akiya T, Takagi M, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol. 2008;9:215–21.

    Article  CAS  PubMed  Google Scholar 

  17. Kato H, Sato A, Fukuda H, Kagami Y, Udagawa H, Togo A, et al. A phase II trial of chemoradiotherapy for stage I esophageal squamous cell carcinoma: Japan Clinical Oncology Group Study (JCOG9708). Jpn J Clin Oncol. 2009;39:638–43.

    Article  PubMed  Google Scholar 

  18. Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N, et al. Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer. 2014;50:1437–45.

    Article  CAS  PubMed  Google Scholar 

  19. Koizumi W, Akiya T, Sato A, Yamaguchi K, Sakuyama T, Nakayama N, et al. Second-line chemotherapy with biweekly paclitaxel after failure of fluoropyrimidine-based treatment in patients with advanced or recurrent gastric cancer: a report from the gastrointestinal oncology group of the Tokyo cooperative oncology group, TCOG GC-0501 trial. Jpn J Clin Oncol. 2009;39:713–9.

    Article  PubMed  Google Scholar 

  20. Yoshida K, Fujii M, Koizumi W, Kim H, Kim YH, Takeuchi M, et al. S-1 plus docetaxel versus S-1 for advanced gastric cancer (START Trial) update 2012 (JACCRO and KCSG study Group), ESMO, Vienna Austria, 2012 (abstract LBA19).

  21. Nashimoto A, Yabusaki H, Matsuki A, Aizawa M. Surgical treatment for curable and incurable recurrent gastric cancer. Gan To Kagaku Ryoho. 2013;40:971–5 (Japanese with English abstract).

    PubMed  Google Scholar 

  22. Nunobe S, Hiki N, Ohyama S, Aikou S, Sano T, Yamaguchi T. Outcome of surgical treatment for patients with locoregional recurrence of gastric cancer. Langenbecks Arch Surg. 2011;396:161–6.

    Article  PubMed  Google Scholar 

  23. Nishimura Y. Rationale for chemoradiotherapy. Int J Clin Oncol. 2004;9:414–20.

    Article  PubMed  Google Scholar 

  24. Tannock IF. Treatment of cancer with radiation and drugs. J Clin Oncol. 1996;14:3156–74.

    CAS  PubMed  Google Scholar 

  25. McGinn CJ, Lawrence TS. Recent advances in the use of radiosensitizing nucleosides. Semin Radiat Oncol. 2001;11:270–80.

    Article  CAS  PubMed  Google Scholar 

  26. Choy H, MacRae R. Irinotecan and radiation in combined-modality therapy for solid tumors. Oncology. 2001;15(Suppl 8):22–8.

    CAS  PubMed  Google Scholar 

  27. Schnirer II, Komaki R, Yao JC, Swisher S, Putnam J, Pisters PW, et al. Pilot study of concurrent 5-fluorouracil/paclitaxel plus radiotherapy in patients with carcinoma of the esophagus and gastroesophageal junction. Am J Clin Oncol. 2001;24:91–5.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Affiliations

  1. Department of Gastroenterology, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara, Kanagawa, 252-0375, Japan

    Kenji Ishido, Katsuhiko Higuchi, Mizutomo Azuma, Tohru Sasaki, Chikatoshi Katada & Wasaburo Koizumi

  2. Research and Development Center for New Frontier, Kitasato University School of Medicine, Sagamihara, Japan

    Satoshi Tanabe

  3. Department of Radiology and Radiation Oncology, Kitasato University School of Medicine, Sagamihara, Japan

    Shouko Komori & Kazushige Hayakawa

  4. Department of Surgery, Kitasato University School of Medicine, Sagamihara, Japan

    Kei Hosoda, Keishi Yamashita & Natsuya Katada

Authors
  1. Kenji Ishido
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Katsuhiko Higuchi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Satoshi Tanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Mizutomo Azuma
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Tohru Sasaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Chikatoshi Katada
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Shouko Komori
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Kazushige Hayakawa
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Kei Hosoda
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Keishi Yamashita
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. Natsuya Katada
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Wasaburo Koizumi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Kenji Ishido.

Ethics declarations

Conflict of interest

None.

Role of the funding source

None of the authors received any financial support for this study.

About this article

Verify currency and authenticity via CrossMark

Cite this article

Ishido, K., Higuchi, K., Tanabe, S. et al. Chemoradiotherapy for patients with recurrent lymph-node metastasis or local recurrence of gastric cancer after curative gastrectomy. Jpn J Radiol 34, 35–42 (2016). https://doi.org/10.1007/s11604-015-0502-6

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11604-015-0502-6

Keywords

  • Recurrent gastric cancer
  • Chemoradiotherapy
  • Unresectable